Perioperative medicine & outcomes
Impact of Intravenous Lidocaine, Dexmedetomidine, and Intrathecal Morphine on Metastasis-Related Biomarkers and Cellular Immune Profiles in Colorectal Surgery: A Prospective, Randomized Controlled Trial
Authors' conclusion
Anesthetic adjuvants exerted differential effects on perioperative biomarkers and immune profiles relevant to tumor progression.
Study context
- Population
- Adults undergoing elective laparoscopic or robotic colorectal cancer resection109 completed and analysed
- Participants
- 114 adults
- Comparison
- IV lidocaine vs dexmedetomidine vs intrathecal morphine
- LIDOn = 38
- DEXn = 34
- Intrathecal morphine (ITM)n = 37
- Primary endpoint
- Plasma matrix metalloproteinase-9 (MMP-9) concentration
- Follow-up
- 1 hour postoperatively
Methodological detailsprospective, patient- and assessor-blinded
- Prospective
- Patient- and assessor-blinded
Primary result
As reported in the abstract
MMP-9 · 1 hour
Difference on the log scale (95% CI)P value
LIDO vs DEX
0.333(0.0642–0.601)
P = 0.009LIDO vs ITM
0.424(0.0248–0.823)
P = 0.033Secondary outcomes
| Outcome | Difference on the logit scale (95% CI) | P value | |
|---|---|---|---|
| CD73+CD8+ T cellsDEX vs LIDO | 0.669 (0.000987–1.34) | P = 0.050 | |
| CD39−CD73−CD8+ T cellsDEX vs ITM | −0.695 (−1.3 to −0.0908) | P = 0.018 | |
| CD39−CD73−CD8+ T cellsDEX vs LIDO | −0.645 (−1.24 to −0.05) | P = 0.029 | |
| −2−1012Difference (linear scale) |
Dynamic pain scores
- Lower with ITM than the other groups
Safety
- Rescue antiemetic use less frequent with DEX
- Other adverse events mild and comparable across groups
Original publication
Impact of Intravenous Lidocaine, Dexmedetomidine, and Intrathecal Morphine on Metastasis-Related Biomarkers and Cellular Immune Profiles in Colorectal Surgery: A Prospective, Randomized Controlled Trial. Anesth Analg. Published 2 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →